Edition:
United States

GlaxoSmithKline PLC (GSK)

GSK on New York Consolidated

40.58USD
22 Sep 2017
Change (% chg)

-- (--)
Prev Close
$40.58
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,836,937
52-wk High
$44.53
52-wk Low
$37.20

Latest Key Developments (Source: Significant Developments)

Avara Pharmaceutical Services acquires a facility from GSK in South Carolina
Thursday, 21 Sep 2017 11:04am EDT 

Sept 21 (Reuters) - Avara Pharmaceutical Services::Avara Pharmaceutical Services acquires consumer healthcare facility from GSK in Aiken, South Carolina.Signed an agreement with GSK to acquire a GSK consumer healthcare manufacturing facility in Aiken, South Carolina​.  Full Article

GSK considering selling off its Horlicks business- BBC
Wednesday, 19 Jul 2017 05:58am EDT 

July 19 (Reuters) - :GSK is considering selling off its Horlicks business- BBC.  Full Article

GSK CEO Walmsley pursuing sale of Maxinutrition brand - Sky News
Thursday, 22 Jun 2017 03:33pm EDT 

June 22 (Reuters) - :Glaxosmithkline Plc CEO Emma Walmsley is pursuing a sale of Maxinutrition, a nutritional products brand - Sky News.  Full Article

GSK announces U.S. regulatory submission seeking expanded indication for Fluarix Quadrivalent for infants 6 months and older
Wednesday, 15 Mar 2017 11:13am EDT 

Glaxosmithkline Plc :GSK announces US regulatory submission seeking expanded indication for Fluarix Quadrivalent (Influenza vaccine) for infants 6 months and older.  Full Article

GSK says asthma drug Nucala (Mepolizumab) meets primary endpoints
Monday, 6 Mar 2017 09:49am EST 

GlaxoSmithKline Plc : Phase IIIB Musca study successfully met all its primary and secondary endpoints . Patients treated with Nucala (Mepolizumab) achieved clinically and statistically significant improvements in quality of life and lung function versus placebo . St. Georges respiratory questionnaire improved by 7.7 units from baseline versus. Placebo (p=0.001) . Lung function (first secondary endpoint), as measured by pre-bronchodilator fev1, increased by 120ml (p=0.001) more than in placebo patients . Asthma control showed a significant improvement versus. Placebo in Mepolizumab treatment group by 0.40 units (p<0.001) .Safety profile of Mepolizumab in Musca study was consistent with product label for Nucala.  Full Article

GSK submits regulatory application in Japan for belimumab
Tuesday, 13 Dec 2016 04:21am EST 

GlaxoSmithKline Plc : Submits regulatory application in Japan for belimumab in systemic lupus erythematosus Further company coverage: [GSK.L] (Bengaluru Newsroom) ((+91 806 749 1136;)).  Full Article

Fimbrion, GSK to develop novel antibacterial therapy for UTIs
Tuesday, 25 Oct 2016 09:45am EDT 

Fimbrion Therapeutics Inc:Fimbrion - co and GSK to develop novel antibacterial therapy for urinary tract infections.  Full Article

Glaxo to pay $20 mln to resolve SEC charges
Friday, 30 Sep 2016 02:15pm EDT 

GlaxoSmithKline PLC : SEC says GlaxoSmithKline PLC to pay $20 million to settle foreign corrupt practices act charges . SEC says civil penalty resolves charges that glaxo's China-based units engaged in pay-to-prescribe schemes to boost sales . SEC says glaxo did not admit or deny wrongdoing . SEC says glaxo's accounting controls failed to prevent schemes, and improper payments were not accurately reflected in its books.  Full Article

GlaxoSmithKline appoints new consumer healthcare CEO
Thursday, 29 Sep 2016 07:40am EDT 

GlaxoSmithKline Plc : GlaxoSmithKline plc appoints Brian McNamara as CEO of GSK consumer healthcare . McNamara succeeds Emma Walmsley who was last week appointed GSK CEO designate succeeding Sir Andrew Witty as GSK CEO . McNamara is currently head of Europe & Americas at GSK consumer healthcare Further company coverage: [GSK.L] (Bengaluru Newsroom) ((+91 806 749 1136;)).  Full Article

Aspen Pharmacare says GSK sells remaining stake in co
Thursday, 29 Sep 2016 03:05am EDT 

Aspen Pharmacare Holdings Ltd : GSK completed an accelerated bookbuild for disposal of its remaining shareholding in aspen .Disposal in no way affects ongoing collaboration between aspen and GSK in South Africa.  Full Article

Photo

FDA declines to approve J&J arthritis drug sirukumab

The U.S. Food and Drug Administration has declined to approve Johnson & Johnson's rheumatoid arthritis drug sirukumab, saying additional clinical data is needed to further evaluate its safety, the company said on Friday.